{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:44Z","timestamp":1761059204196},"reference-count":7,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1568,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1600-0609.2011.01603.x","type":"journal-article","created":{"date-parts":[[2011,4,7]],"date-time":"2011-04-07T16:45:26Z","timestamp":1302194726000},"page":"548-549","source":"Crossref","is-referenced-by-count":1,"title":["Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia"],"prefix":"10.1111","volume":"86","author":[{"given":"Igor","family":"Novitzky-Basso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,17]]},"reference":[{"key":"10.1111\/j.1600-0609.2011.01603.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01603.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"10","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01603.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"Suppl","key":"10.1111\/j.1600-0609.2011.01603.x-BIB4|cit4","article-title":"Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety","volume":"26","author":"Khoury","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1111\/j.1600-0609.2011.01603.x-BIB5|cit5","article-title":"Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)","volume":"26","author":"Jabbour","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01603.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2133.2006.07262.x","article-title":"Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia","volume":"154","author":"Deguchi","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1600-0609.2011.01603.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (sti571) in Philadelphia chromosome-positive leukaemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01603.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01603.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T08:18:07Z","timestamp":1637482687000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01603.x"}},"subtitle":["Letter to the Editor"],"short-title":[],"issued":{"date-parts":[[2011,5,17]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01603.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,17]]}}}